Drug Profile
Bizaxofusp - Medicenna Therapeutics
Alternative Names: cpIL4-PE; IL-4 Superkines™; IL4-EC; IL4-PE; Interleukin-4 Empowered Cytokine™; Interleukin-4 PE38KDEL cytotoxin; Interleukin-4 PE38KDEL immunotoxin; Interleukin-4 Pseudomonas toxin; Interleukin-4(38-37)-PE38KDEL; Interleukin-4-Pseudomonas exotoxin; Interleukin-4-Pseudomonas exotoxin fusion protein; INxin; MDNA 55; NBI-3001; PRX321Latest Information Update: 20 Feb 2024
Price :
$50
*
At a glance
- Originator National Institutes of Health (USA); Neurocrine Biosciences
- Developer Medicenna Therapeutics; Neurocrine Biosciences; Sophiris Bio
- Class Antineoplastics; Immunotoxins; Interleukins; Recombinant fusion proteins
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Brain metastases; Glioblastoma
- No development reported Bladder cancer; Brain cancer; Diffuse intrinsic pontine glioma
- Discontinued Solid tumours
Most Recent Events
- 14 Feb 2024 Bizaxofusp plans to seek Breakthrough therapy designation from the US FDA for Glioblastoma
- 14 Feb 2024 Medicenna Therapeutics announces intention to submit regulatory application to European Union and USA
- 17 Nov 2023 Updated efficacy and safety data from a phase IIb trial in Glioblastoma presented at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO-2023)